Skip to main content

Advertisement

SpringerLink
Log in

After GLP-1, what’s next for weight loss?

  • News
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

The GLP-1 agonist Wegovy has re-energized the hunt for obesity treatments. Alternatives — ranging from bitter taste compounds to lean muscle boosters and bacteria — are already in the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. London, UK

    Melanie Senior

Authors
  1. Melanie Senior
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Senior, M. After GLP-1, what’s next for weight loss?. Nat Biotechnol 41, 740–743 (2023). https://doi.org/10.1038/s41587-023-01818-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-01818-4

  • Springer Nature America, Inc.

Search

Navigation